Jubilant Ingrevia Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Jubilant Ingrevia Ltd filed with BSE on 29 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Jubilant Ingrevia reported its highest quarterly revenue and EBITDA in 14 quarters for Q4 FY26, with revenue at Rs. 1,179 crore up 12% year-on-year and EBITDA at Rs. 172 crore up 11% year-on-year. Management attributed the performance to volume growth across Specialty Chemicals, Nutrition, and Chemical Intermediates segments, along with effective cost pass-through amid Middle East-related raw material disruptions. The company also completed the acquisition of Remidex Pharma to expand its Human Nutrition business and commissioned its Bharuch CDMO plant during the year.
Numbers mentioned
Revenue: Rs. 1,179 crore (Q4 FY26)
p. 4
“Q4 recorded highest revenue in 14 quarters at Rs. 1,179 crore, up 12% year-on-year, driven by 10% volume growth.”
Deepak Jain, page 4 of the filed PDF · View the filing
EBITDA: Rs. 172 crore (Q4 FY26)
p. 4
“EBITDA stood at Rs. 172 crore, up 11% year-on-year and 26% quarter-on-quarter.”
Deepak Jain, page 4 of the filed PDF · View the filing
PAT: Rs. 86 crore (Q4 FY26)
p. 4
“PAT was Rs. 86 crore, up 17% year-on-year and 84% quarter-on-quarter.”
Deepak Jain, page 4 of the filed PDF · View the filing
Net debt to EBITDA: 0.99x (FY26)
p. 5
“Net debt by EBITDA improved to 0.99x.”
Deepak Jain, page 5 of the filed PDF · View the filing
Specialty Chemicals revenue: Rs. 516 crore (Q4 FY26)
p. 5
“In Specialty Chemicals, revenue stood at Rs. 516 crore, rose 6% year-on-year and 13% quarter-on-quarter.”
Deepak Jain, page 5 of the filed PDF · View the filing
Specialty Chemicals EBITDA margin: 27% (Q4 FY26)
p. 5
“EBITDA stood at Rs. 139 crore with margins at 27%, which we have maintained for last 6 quarters.”
Deepak Jain, page 5 of the filed PDF · View the filing
Specialty Chemicals FY26 revenue: Rs. 1,937 crore (FY26)
p. 5
“FY26 revenue stood at Rs. 1,937 crore, up 7%; EBITDA stood at Rs. 510 crore, up 21%.”
Deepak Jain, page 5 of the filed PDF · View the filing
Nutrition segment revenue: Rs. 230 crore (Q4 FY26)
p. 5
“In Nutrition business, segment revenue stood at Rs. 230 crore, up 21% year-on-year and 15% quarter-on-quarter.”
Deepak Jain, page 5 of the filed PDF · View the filing
Nutrition segment EBITDA: Rs. 32 crore (Q4 FY26)
p. 5
“Segment EBITDA stood at Rs. 32 crore, up by 42% quarter-on-quarter and margin stood at 14%.”
Deepak Jain, page 5 of the filed PDF · View the filing
Nutrition FY26 revenue and EBITDA: Rs. 790 crore revenue, Rs. 100 crore EBITDA (FY26)
p. 5
“FY26 revenue stood at Rs. 790 crore and EBITDA at Rs. 100 crore.”
Deepak Jain, page 5 of the filed PDF · View the filing
Chemical Intermediates revenue: Rs. 433 crore (Q4 FY26)
p. 5
“In Chemical Intermediates business, revenue stood at Rs. 433 crore, up 15% year-on-year and 10% quarter-on-quarter.”
Deepak Jain, page 5 of the filed PDF · View the filing
Final dividend: Rs. 2.5 per share (FY26)
p. 4
“The Board has recommended a final dividend of Rs. 2.5 per share, 250% and taking a total FY '26 dividend to Rs. 5 per share 500% with the total cash outflow of Rs. 79.8 crore.”
Shyam Bhartia, page 4 of the filed PDF · View the filing
Net working capital: 59 days (FY26)
p. 6
“improved net working capital at 59 days, leading to a more efficient balance sheet and a net debt-to-EBITDA ratio of 0.99.”
Deepak Jain, page 6 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA growth — at least 20% year-on-year · FY27
stated firmly by Deepak Jain
p. 9
“But we will stick to our overall guidance of achieving at least 20% growth in EBITDA through the year.”
Deepak Jain, page 9 of the filed PDF · View the filing
Revenue and EBITDA growth — Q1 FY27 and coming quarters
stated firmly by Shyam Bhartia
p. 4
“We are expecting a sequential growth in revenue and EBITDA in coming quarters, starting from Q1 FY '27 itself.”
Shyam Bhartia, page 4 of the filed PDF · View the filing
Capex — Rs. 400 crore to Rs. 500 crore · FY27
stated firmly by Varun Gupta
p. 10
“in 2027, as we have indicated earlier, we will continue with the range of Rs. 400 crore to Rs. 500 crore of yearly capex to continue to invest behind our growth.”
Varun Gupta, page 10 of the filed PDF · View the filing
Specialty Chemicals EBITDA margin — 23% to 25%
stated firmly by Deepak Jain
p. 17
“the sustainable margin for our Specialty Chemical portfolio as a whole should be between 23% to 25% post adjustment of the corporate overheads.”
Deepak Jain, page 17 of the filed PDF · View the filing
Gajraula MPP plant commissioning — quarter 4
stated firmly by Varun Gupta
p. 10
“The big capex is coming into Gajraula MPP, which we have announced earlier, which will be finished this year and will go in to commence production in quarter 4.”
Varun Gupta, page 10 of the filed PDF · View the filing
Pharma CDMO business scale — 3x to 4x of its current size
stated as an aspiration by Deepak Jain
p. 15
“we have announced and we presented even in our Investor Day presentation that the pharma CDMO business we want to take it to at least 3x to 4x of its current size.”
Deepak Jain, page 15 of the filed PDF · View the filing
EBITDA growth organically — FY30
stated as an aspiration by Deepak Jain
p. 10
“We still feel confident that by FY30, we should be able to take our EBITDA organically to the ranges that we announced in the Investor Day.”
Deepak Jain, page 10 of the filed PDF · View the filing
Acetyls inventory impact — Q1 and Q2 FY27
stated conditionally by Deepak Jain
p. 7
“we are hopeful that whatever inventory impact has to come, we will be able to nullify within this quarter or at best in the early part of next quarter and hence, minimize any negative impact coming from that in Q2.”
Deepak Jain, page 7 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said benefits from earlier inventory purchases would continue into Q1 and expects to minimize negative impact by Q2.
Answered by Deepak Jain
Asked by Siddharth Gadekar: How should spreads in Chemical Intermediates be viewed in Q1 given sharp improvement in ethyl acetate and acetic anhydride spreads, and should inventory losses be expected beyond Q1?
p. 7
“we are hopeful that those benefits will continue in Q1 as well in a strong way.”
Deepak Jain, page 7 of the filed PDF · View the filing
All CDMO revenue sits within Specialty Chemicals and has been growing 30-40% annually.
Answered by Deepak Jain
Asked by Siddharth Gadekar: What was CDMO revenue growth in FY26 and is it all classified under Specialty Chemicals?
p. 7
“it has been growing at a very healthy rate, almost 30% to 40% every year.”
Deepak Jain, page 7 of the filed PDF · View the filing
Management reiterated a full-year EBITDA growth aspiration of at least 20%, declining to give quarterly figures due to timing variability.
Answered by Deepak Jain
Asked by Abhijit Akella: Can management quantify expected quarterly or annual EBITDA growth for the coming year?
p. 8
“we aspire to get at least 20% year-on-year growth in EBITDA on the full year basis.”
Deepak Jain, page 8 of the filed PDF · View the filing
Management confirmed continued capex in the Rs 400-500 crore range with the Gajraula MPP plant as the major project.
Answered by Varun Gupta
Asked by Abhijit Akella: What capex should be modeled for FY27 given capital work-in-progress reduction?
p. 10
“we will continue with the range of Rs. 400 crore to Rs. 500 crore of yearly capex to continue to invest behind our growth.”
Varun Gupta, page 10 of the filed PDF · View the filing
Management said the company is naturally hedged given large dollar-denominated imports, so the benefit will not be linear.
Answered by Deepak Jain
Asked by Harsh Shah: Does rupee depreciation since the $300 million contract was signed benefit the company through higher rupee revenues?
p. 11
“we still feel there will be some positive impact, but it will not be just as linear, as you said that Rs. 84 becoming Rs. 95 and what is the benefit coming into the P&L.”
Deepak Jain, page 11 of the filed PDF · View the filing
Management said revenues are currently small with a slow ramp-up expected due to the sensitive nature of the segment.
Answered by Deepak Jain
Asked by Harsh Shah: When can semiconductor chemical revenues be expected?
p. 11
“We already have some revenues coming in, but very small.”
Deepak Jain, page 11 of the filed PDF · View the filing
Management named fine chemicals, CDMO, nutrition and acetyls recovery as growth pillars, and said the customer has committed to make them whole for any volume shortfall.
Answered by Deepak Jain
Asked by Archit Joshi: What are the multi-year growth drivers and is there visibility on recouping volumes from the large agro innovator contract?
p. 13
“we do have an understanding as well as commitment from them that just in case there is any shortfall in volumes, they will make us whole as per the contractual agreement.”
Deepak Jain, page 13 of the filed PDF · View the filing
Management said the pipeline is broad-based with about 70% non-Pyridine chemistries, and roughly one-third to 40% now comes from innovators.
Answered by Deepak Jain
Asked by Archit Joshi: Is the pharma CDMO pipeline growth linked only to Pyridine chemistry or broader capabilities, and is there scope with pharma majors?
p. 14
“only 25% to 30% of this pipeline we have created in pharma is Pyridine-based, 70% is non-Pyridine.”
Deepak Jain, page 14 of the filed PDF · View the filing
Management explained that Pyridine and Beta Picoline prices move inversely and currently Pyridine is at a low point while Beta Picoline is high.
Answered by Deepak Jain
Asked by Srishti Jain: What is the demand-supply scenario in Pyridine and reasons for muted pricing?
p. 16
“Right now, as we speak, for Pyridine prices, they are very low, in fact, at the rock bottom right now.”
Deepak Jain, page 16 of the filed PDF · View the filing
Management reiterated a sustainable range of 23-25% after adjusting for corporate overheads.
Answered by Deepak Jain
Asked by Srishti Jain: What is the sustainable EBITDA margin for Specialty Chemicals given current elevated levels of 26-27%?
p. 17
“We are confident of maintaining the EBITDA margin in Specialty Chemicals at that level going forward as well.”
Deepak Jain, page 17 of the filed PDF · View the filing
Management said the customer has not confirmed final volumes yet but hopes to at least match last year's volumes.
Answered by Deepak Jain
Asked by Nitesh Dhoot: What is the scale-up opportunity for the smaller agri contract executed last year?
p. 18
“we do hope that we will get at least as much as we got last year, but hopefully, we should be able to top it up with something more.”
Deepak Jain, page 18 of the filed PDF · View the filing
Management said PC-grade niacinamide scaled up quickly to about 50% of estimated volumes, while Niacin ramp-up is more gradual.
Answered by Deepak Jain
Asked by Nitesh Dhoot: What are utilization levels for the human-grade B3 (niacinamide) plant?
p. 18
“I think we are already doing almost 50% of what we had estimated in terms of volumes.”
Deepak Jain, page 18 of the filed PDF · View the filing
Risks flagged
Middle East disruptions raised raw material and input costs
p. 4
“Despite Middle East disruptions impacting supply and prices, our diversified sourcing and agility ensured minimal disruption with effective cost pass-through.”
Deepak Jain, page 4 of the filed PDF · View the filing
Potential inventory losses in the acetyls business from falling acetic acid prices
p. 7
“As you rightly said, we are already seeing acetic acid prices coming down.”
Deepak Jain, page 7 of the filed PDF · View the filing
Agrochemical industry slowdown and cost pressure from China
p. 12
“The challenge in agrochemical industry, as I think most of you already know has been that it has been moving very slowly and there are massive cost pressures coming from China as well.”
Deepak Jain, page 12 of the filed PDF · View the filing
Volume uncertainty in the large agro innovator contract due to customer difficulties
p. 13
“Of course, the customer is going through some tough times and we are in constant touch with them.”
Deepak Jain, page 13 of the filed PDF · View the filing
Natural mortality rate of early-stage pharma CDMO molecules
p. 15
“But at the same time, there will be some natural mortality rate to these molecules.”
Deepak Jain, page 15 of the filed PDF · View the filing
Slow, cautious customer adoption in semiconductor chemicals segment
p. 11
“So we expect a slow ramp-up in that segment, but our number of opportunities are definitely increasing.”
Deepak Jain, page 11 of the filed PDF · View the filing
Volatility in Pyridine and Beta Picoline pricing
p. 16
“the Pyridine and Picoline pricing, if you track back last 10, 15, 20 years, you will always see some volatility in that”
Deepak Jain, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.